Atomwise

Atomwise is a pioneer in applying deep learning to structure-based drug design. Its AtomNet platform uses convolutional neural networks trained on millions of experimental affinity measurements to predict the binding of small molecules to protein targets, enabling rapid virtual screening of billions of compounds. The company has established a broad network of academic and pharmaceutical collaborations.

$123M

Total raised

AtomNet is a deep learning neural network for structure-based drug design that predicts binding affinity of small molecules to protein targets. It uses 3D convolutional neural networks to evaluate molecular interactions, enabling virtual screening of ultra-large compound libraries.